BeOne Medicines Ltd. (ONC) Q2 2026 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Beone Medicines Ltd. Class A.

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:05.700 Good day, everyone. Welcome to B1 Medicine's Q2 2026 earnings call webcast. 00:00:05.700 -- 00:00:09.006 All lines have been placed on mute to prevent any background noise. 00:00:09.006 -- 00:00:12.291 After the speaker's remark, there will be a question and answer session. 00:00:12.291 -- 00:00:16.354 At this time, I would like to turn the call over to the company. 00:00:17.517 -- 00:00:20.138 Hello and welcome. Thank you for joining us today. 00:00:20.138 -- 00:00:23.839 I'm Dan Maller, Head of Investor Relations at B1 Medicines. 00:00:23.839 -- 00:00:28.581 Before we begin, please note that you can find additional materials, including a replay 00:00:28.581 -- 00:00:33.563 of today's webcast and presentation, on the Investor Relations section of our website, 00:00:33.563 -- 00:00:35.563 ir.b1medicines.com. 00:00:37.044 -- 00:00:42.146 I would like to remind all participants that during this call, you may make forward-looking 00:00:42.146 -- 00:00:46.068 statements regarding, among other things, the company's future prospects and business 00:00:46.068 -- 00:00:50.975 strategy. Actual results may differ materially from those indicated in the forward-looking 00:00:50.975 -- 00:00:55.599 statements as a result of various factors, including those risks discussed in our most 00:00:55.599 -- 00:00:59.121 recent periodic report filed with the SEC. 00:00:59.121 -- 00:01:03.505 Please also carefully review the forward-looking statements disclaimer in the slide deck 00:01:03.505 -- 00:01:06.187 that accompanies this presentation. 00:01:06.187 -- 00:01:10.290 Reconciliations between GAAP and non-GAAP financial measures discussed on this call are 00:01:10.290 -- 00:01:14.073 provided in the appendix to our presentation, which is posted to our...